|
BRPI0919841A2
(pt)
|
2008-10-01 |
2014-11-18 |
Micromet Ag |
Anticorpo de cadeia unica biespecifico de psmaxcd3, especifico de especies cruzadas
|
|
BRPI0919840B1
(pt)
*
|
2008-10-01 |
2023-02-28 |
Amgen Research (Munich) Gmbh |
Molécula de anticorpo de cadeia única biespecífica, seu uso, e composição farmacêutica que a compreende
|
|
EP2352763B2
(en)
*
|
2008-10-01 |
2022-09-21 |
Amgen Research (Munich) GmbH |
Bispecific single chain antibodies with specificity for high molecular weight target antigens
|
|
AU2009299794B2
(en)
*
|
2008-10-01 |
2015-08-13 |
Amgen Research (Munich) Gmbh |
Cross-species-specific single domain bispecific single chain antibody
|
|
LT2647707T
(lt)
|
2010-11-30 |
2018-11-12 |
Chugai Seiyaku Kabushiki Kaisha |
Citotoksiškumą indukuojantis terapinis agentas
|
|
SG194510A1
(en)
|
2011-04-22 |
2013-12-30 |
Emergent Product Dev Seattle |
Prostate-specific membrane antigen binding proteins and related compositionsand methods
|
|
ME03440B
(me)
*
|
2011-05-21 |
2020-01-20 |
Macrogenics Inc |
Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
HRP20191865T1
(hr)
*
|
2013-01-14 |
2020-01-10 |
Xencor, Inc. |
Novi heterodimerni proteini
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
GB201303308D0
(en)
*
|
2013-02-25 |
2013-04-10 |
Oxford Biotherapeutics Ltd |
Therapeutic and diagnostic target
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
ME03675B
(me)
|
2013-07-05 |
2020-10-20 |
Genmab As |
Humanizovana ili himerna anтi-cd3 antiтela
|
|
CA2918795A1
(en)
|
2013-07-25 |
2015-01-29 |
Cytomx Therapeutics, Inc. |
Multispecific antibodies, multispecific activatable antibodies and methods of using the same
|
|
KR102357961B1
(ko)
|
2013-12-17 |
2022-02-08 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
EP3954713A3
(en)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispecific antibodies that bind to cd38 and cd3
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
US11505605B2
(en)
|
2014-05-13 |
2022-11-22 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
|
US9212225B1
(en)
|
2014-07-01 |
2015-12-15 |
Amphivena Therapeutics, Inc. |
Bispecific CD33 and CD3 binding proteins
|
|
US9884921B2
(en)
|
2014-07-01 |
2018-02-06 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
WO2016014974A2
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
CA2956471C
(en)
*
|
2014-07-31 |
2024-09-10 |
Amgen Res Munich Gmbh |
OPTIMIZED CONSTRUCTIONS OF SINGLE-CATENAL, BI-SPECIFIC, AND CROSS-SPECIFIC ANTIBODY
|
|
EP2982693A1
(en)
|
2014-08-07 |
2016-02-10 |
Affimed Therapeutics AG |
CD3 binding domain
|
|
SG11201700901SA
(en)
|
2014-08-08 |
2017-03-30 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3223907A2
(en)
|
2014-11-26 |
2017-10-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cd38
|
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
|
HK1250997A1
(zh)
*
|
2015-05-01 |
2019-01-18 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
|
CA2985125A1
(en)
*
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
US11400157B2
(en)
|
2015-05-13 |
2022-08-02 |
Chugai Seiyaku Kabushiki Kaisha |
Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion
|
|
KR102537102B1
(ko)
|
2015-05-29 |
2023-05-25 |
엠피베나 테라퓨틱스, 인크. |
이중특이적 cd33 및 cd3 결합 단백질을 사용하는 방법
|
|
JOP20160154B1
(ar)
*
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR IMPROVING THE HUMORAL IMMUNE REACTION
|
|
KR20180085800A
(ko)
*
|
2015-12-07 |
2018-07-27 |
젠코어 인코포레이티드 |
Cd3 및 psma에 결합하는 이종이합체성 항체
|
|
LT3411404T
(lt)
*
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
|
US11414497B2
(en)
|
2016-04-13 |
2022-08-16 |
Orimabs Ltd. |
Anti-PSMA antibodies and use thereof
|
|
IL263542B2
(en)
|
2016-06-14 |
2024-10-01 |
Xencor Inc |
Bispecific antibodies inhibit immunological checkpoint
|
|
EP3471773A4
(en)
|
2016-06-21 |
2020-07-08 |
Teneobio, Inc. |
ANTIBODIES BINDING CD3
|
|
KR20190020341A
(ko)
|
2016-06-28 |
2019-02-28 |
젠코어 인코포레이티드 |
소마토스타틴 수용체 2에 결합하는 이종이량체 항체
|
|
UA126384C2
(uk)
*
|
2016-09-14 |
2022-09-28 |
Тенеобіо, Інк. |
Антитіло, яке зв'язує cd3
|
|
PT3512878T
(pt)
|
2016-09-15 |
2020-11-20 |
Novimmune Sa |
Apresentação de anticorpo biespecífico na superfície de fagos
|
|
CA3037380A1
(en)
*
|
2016-10-11 |
2018-04-19 |
Agenus Inc. |
Anti-lag-3 antibodies and methods of use thereof
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
IL267485B2
(en)
|
2016-12-21 |
2024-01-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies and uses thereof
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
ES2955074T3
(es)
|
2017-02-20 |
2023-11-28 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a HER2, NKG2D Y CD16
|
|
TWI710637B
(zh)
*
|
2017-03-29 |
2020-11-21 |
臺北醫學大學 |
具抗原專一性的t細胞及其用途
|
|
CN110945026B
(zh)
|
2017-06-20 |
2024-03-19 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
KR20250007003A
(ko)
|
2017-06-20 |
2025-01-13 |
테네오바이오, 인코포레이티드 |
항-bcma 중쇄-단독 항체
|
|
HRP20230675T1
(hr)
*
|
2017-08-03 |
2023-09-29 |
Alector Llc |
Anti-trem2 protutijela i postupci njihove uporabe
|
|
IL321773A
(en)
|
2017-10-14 |
2025-08-01 |
Cytomx Therapeutics Inc |
Activatable antibodies and methods for preparing them
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
AU2018366199A1
(en)
|
2017-11-08 |
2020-05-28 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-PD-1 sequences
|
|
MX2020006322A
(es)
|
2017-12-19 |
2020-09-18 |
Xencor Inc |
Proteinas de fusion il-2 fc modificadas.
|
|
MX2020006494A
(es)
|
2017-12-22 |
2020-11-24 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd22.
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
|
CA3090236A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
|
|
MX2020008289A
(es)
|
2018-02-08 |
2020-09-25 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso.
|
|
SG11202007482WA
(en)
|
2018-02-08 |
2020-09-29 |
Dragonfly Therapeutics Inc |
Antibody variable domains targeting the nkg2d receptor
|
|
KR102832460B1
(ko)
|
2018-02-20 |
2025-07-11 |
드래곤플라이 쎄라퓨틱스, 인크. |
Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
|
|
JP7377590B2
(ja)
|
2018-03-14 |
2023-11-10 |
ノビミューン エスアー |
抗cd3イプシロン抗体およびそれを使用する方法
|
|
CN112469477A
(zh)
|
2018-04-04 |
2021-03-09 |
Xencor股份有限公司 |
与成纤维细胞活化蛋白结合的异源二聚体抗体
|
|
AU2019256539A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
FI3830132T3
(fi)
*
|
2018-07-31 |
2023-01-13 |
|
Humanisoituja vasta-aineita psma:ta vastaan
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
MX2021001527A
(es)
|
2018-08-08 |
2021-06-15 |
Dragonfly Therapeutics Inc |
Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor.
|
|
MA53293A
(fr)
|
2018-08-08 |
2021-11-17 |
Dragonfly Therapeutics Inc |
Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
CN113710707B
(zh)
|
2019-04-05 |
2024-05-31 |
特尼奥生物股份有限公司 |
结合于psma的重链抗体
|
|
CN110156890B
(zh)
*
|
2019-04-09 |
2021-02-02 |
苏州大学 |
Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用
|
|
CN119564852A
(zh)
|
2019-06-14 |
2025-03-07 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
WO2021004400A1
(zh)
*
|
2019-07-06 |
2021-01-14 |
苏州克睿基因生物科技有限公司 |
一种表达cd3抗体受体复合物的免疫细胞及其用途
|
|
JP2022542431A
(ja)
*
|
2019-07-30 |
2022-10-03 |
キューエルエスエフ バイオセラピューティクス, インコーポレイテッド |
二重特異性抗lrrc15及びcd3イプシロン抗体
|
|
BR112022011357A2
(pt)
|
2019-12-13 |
2022-08-23 |
Genentech Inc |
Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
|
|
AU2021207470A1
(en)
|
2020-01-13 |
2022-07-07 |
Aptevo Research And Development Llc |
Formulations for protein therapeutics
|
|
BR112022013730A2
(pt)
|
2020-01-13 |
2022-10-11 |
Aptevo Res & Development Llc |
Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
|
|
MX2022013944A
(es)
|
2020-05-06 |
2022-11-30 |
Dragonfly Therapeutics Inc |
Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
KR102607909B1
(ko)
|
2020-08-19 |
2023-12-01 |
젠코어 인코포레이티드 |
항-cd28 조성물
|
|
US12351643B2
(en)
|
2020-11-04 |
2025-07-08 |
Genentech, Inc. |
Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies
|
|
TWI888665B
(zh)
|
2020-11-04 |
2025-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
|
CR20230229A
(es)
|
2020-11-06 |
2023-09-05 |
Amgen Res Munich Gmbh |
Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
|
|
US20240034806A1
(en)
*
|
2020-12-09 |
2024-02-01 |
Janux Therapeutics, Inc. |
Compositions and methods related to tumor activated antibodies targeting trop2 and effector cell antigens
|
|
MX2023006817A
(es)
|
2020-12-09 |
2023-08-14 |
Janux Therapeutics Inc |
Composiciones y metodos relacionados con anticuerpos activados por tumores dirigidos a psma y antigenos de celulas efectoras.
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
JP2024511319A
(ja)
|
2021-03-09 |
2024-03-13 |
ゼンコア インコーポレイテッド |
Cd3及びcldn6に結合するヘテロ二量体抗体
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Cd3及びgpc3に結合するヘテロ二量体抗体
|
|
MX2023012408A
(es)
|
2021-04-30 |
2023-10-31 |
Hoffmann La Roche |
Dosis para tratamiento conjunto con anticuerpo biespecifico anti-cd20/anti-cd3 y conjugado anticuerpo farmaco anti-cd79b.
|
|
US20240384006A1
(en)
|
2021-05-06 |
2024-11-21 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
|
US12291575B2
(en)
|
2021-05-14 |
2025-05-06 |
Genentech, Inc. |
Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
|
|
WO2022246244A1
(en)
|
2021-05-21 |
2022-11-24 |
Aptevo Research And Development Llc |
Dosing regimens for protein therapeutics
|
|
WO2023183231A1
(en)
|
2022-03-21 |
2023-09-28 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
|
IL316597A
(en)
|
2022-05-12 |
2024-12-01 |
Amgen Res Munich Gmbh |
Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
|